Literature DB >> 21268059

Control of RUNX3 by histone methyltransferases.

You Mie Lee1.   

Abstract

Runt-related (RUNX) family proteins function as context-dependent transcription factors during developmental processes such as hematopoiesis, neurogenesis, and osteogenesis. RUNX3 is involved in a variety of physiological processes including neurogenesis, thymopoiesis, and dendritic cell maturation. A large amount of information indicates that RUNX3 may be a tumor suppressor. Recent data suggest that the molecular mechanism responsible for RUNX3 deficiency in numerous cancers is a primarily epigenetic silencing. The present review focuses on the regulation of RUNX3 gene expression by histone modification, emphasizing histone methylation at the RUNX3 promoter and inactivation of protein itself. Inactivation of the promoter and protein can be the results of various chemical modifications, including methylation by histone methyltransferase. Inactivation of RUNX3 may contribute to the tumor initiation, progression and pathogenesis in specific microenvironmental contexts. Finally, this review describes the reactivation of RUNX3 by epigenetic regulatory agents.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21268059     DOI: 10.1002/jcb.22969

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  13 in total

1.  Stabilization of RNT-1 protein, runt-related transcription factor (RUNX) protein homolog of Caenorhabditis elegans, by oxidative stress through mitogen-activated protein kinase pathway.

Authors:  Kiho Lee; Jiwon Shim; Jaebum Bae; Young-Joon Kim; Junho Lee
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

2.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

3.  Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription.

Authors:  Daniel J Purcell; Omar Khalid; Chen-Yin Ou; Gillian H Little; Baruch Frenkel; Sanjeev K Baniwal; Michael R Stallcup
Journal:  J Cell Biochem       Date:  2012-07       Impact factor: 4.429

Review 4.  Microbiota impact on the epigenetic regulation of colorectal cancer.

Authors:  Tao Yang; Jennifer L Owen; Yaíma L Lightfoot; Michael P Kladde; Mansour Mohamadzadeh
Journal:  Trends Mol Med       Date:  2013-09-16       Impact factor: 11.951

Review 5.  Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.

Authors:  Yuewu Yang; Zhiqiang Ye; Zengcheng Zou; Gemin Xiao; Gangjian Luo; Hongzhi Yang
Journal:  Tumour Biol       Date:  2014-07-19

6.  Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors.

Authors:  C B Avci; Y Dodurga; S Y Susluer; Z O D Sıgva; M Yucebas; H O Caglar; T Akalin; T Dalbasti; N Oktar; C Gunduz
Journal:  Ir J Med Sci       Date:  2013-08-11       Impact factor: 1.568

7.  Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.

Authors:  Lijun Xu; Hongwen Lan; Yushu Su; Jun Li; Jingwen Wan
Journal:  Drug Des Devel Ther       Date:  2015-06-03       Impact factor: 4.162

8.  Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis.

Authors:  Wei-Ping Mu; Jian Wang; Qiong Niu; Ning Shi; Hai-Feng Lian
Journal:  Onco Targets Ther       Date:  2014-07-10       Impact factor: 4.147

9.  Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.

Authors:  Yi Wang; Xiuguang Qin; Jieqing Wu; Bo Qi; Yipeng Tao; Wenju Wang; Fulei Liu; Hanchen Li; Baosheng Zhao
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

10.  Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis.

Authors:  Claudia Figueroa-Romero; Junguk Hur; Diane E Bender; Colin E Delaney; Michael D Cataldo; Andrea L Smith; Raymond Yung; Douglas M Ruden; Brian C Callaghan; Eva L Feldman
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.